XPLR Infrastructure, LP (NYSE: XIFR) today announced the results of the previously announced cash tender offer (the “offer”) by its direct subsidiary, XPLR Infrastructure Operating Partners, LP (“XPLR OpCo”) (the “offeror”), for any and all of its outstanding 3.875% senior notes due 2026 (the “OpCo 2026 notes”). https://mma.prnewswire.com/media/2607570/XPLR_logo_TM_c_1_Logo.jpg As of 5:00 p.m., New York City […]

ABS is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize elevated levels of soluble IL7 receptor. Autoimmunity BioSolutions (ABS), is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or “correct” elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. https://mma.prnewswire.com/media/2564762/Autoimmunity_BioSolutions_Logo.jpg ABS announced key

Cheetah Mobile Inc. (“Cheetah Mobile” or the “Company”) (NYSE: CMCM), a China-based IT company, today announced that it will report its financial results for the third quarter 2025 before the U.S. market opens on Wednesday, November 26, 2025. The earnings release will be available on the Company's investor relations website at http://ir.cmcm.com. Cheetah Mobile's management

Fujitsu today announced its recognition as an Emerging Leader in the Gartner Emerging Market Quadrant for Generative AI Engineering in the Innovation Guide for Generative AI Engineering, published on November 13, 2025. Since March 2025, Fujitsu has remained the only Japan-headquartered company to be recognized as an Emerging Leader in this report. Fujitsu has been

Avicanna Announces Pre-Clinical Data Supporting Enhanced Absorption and Patent Filing for Novel Oral Delivery Platform GlobeNewswire November 19, 2025 PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in preclinical studies Provisional patent application on the novel drug delivery platform which can be loaded into products such as tablets, capsules, sachets

FG Nexus CEO of Digital Assets Maja Vujinovic to Participate in the 2025 Clear Street Disruptive Technology Conference GlobeNewswire November 19, 2025 Charlotte, NC, Nov. 19, 2025 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”), today announced that CEO of Digital Assets Maja Vujinovic will participate in the panel “Tokenizing

H2O America Announces Deferral of San Jose Water Company's Cost of Capital Filing to May 1, 2027 GlobeNewswire November 19, 2025 Upholds San Jose Water's current 9.81% allowed return on equity (ROE), which is the CPUC-approved 10.01% base ROE prior to a 20-basis-point reduction related to the Water Conservation Memorandum Account (WCMA) Timing for next

Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference GlobeNewswire November 19, 2025 NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,

Nayax Reports Third Quarter 2025 Results GlobeNewswire November 19, 2025 Revenue of $104.3 million, processing revenue growth of 33% Organic Revenue growth of 25% (1) Net income of $3.5 million with Adjusted EBITDA of $18.2 million (1) Updates 2025 revenue and Adjusted EBITDA guidance to reflect delays in timing of M&As Reaffirming full year Organic

Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd GlobeNewswire November 19, 2025 FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes